Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose

Chad J. Roy, A. Paige Adams, Eryu Wang, Kenneth Plante, Rodion Gorchakov, Robert Seymour, Heather Vinet-Oliphant, Scott Weaver

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes major epidemics of rash, fever, and debilitating arthritis. Currently, there are no vaccines or antivirals available for prevention or treatment. We therefore generated 2 live-attenuated vaccine candidates based on the insertion of a picornavirus internal ribosome entry site (IRES) sequence into the genome of CHIKV. Vaccination of cynomolgus macaques with a single dose of either vaccine produced no signs of disease but was highly immunogenic. After challenge with a subcutaneous inoculation of wild-type CHIKV, both vaccine candidates prevented the development of detectable viremia. Protected animals also exhibited no significant changes in core body temperature or cardiovascular rhythm, whereas sham-vaccinated animals showed hyperthermia, followed by sustained hypothermia, as well as significant changes in heart rate. These CHIKV/IRES vaccine candidates appear to be safe and efficacious, supporting their strong potential as human vaccines to protect against CHIKV infection and reduce transmission and further spread.

Original languageEnglish (US)
Pages (from-to)1891-1899
Number of pages9
JournalJournal of Infectious Diseases
Volume209
Issue number12
DOIs
StatePublished - Jun 15 2014

Fingerprint

Chikungunya virus
Primates
Vaccines
Fever
Alphavirus
Picornaviridae
Attenuated Vaccines
Infectious Disease Transmission
Viremia
Macaca
Exanthema
Culicidae
Hypothermia
Body Temperature
Arthritis
Antiviral Agents
Vaccination
Heart Rate
Genome

Keywords

  • Chikungunya virus
  • nonhuman primates
  • viral vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. / Roy, Chad J.; Adams, A. Paige; Wang, Eryu; Plante, Kenneth; Gorchakov, Rodion; Seymour, Robert; Vinet-Oliphant, Heather; Weaver, Scott.

In: Journal of Infectious Diseases, Vol. 209, No. 12, 15.06.2014, p. 1891-1899.

Research output: Contribution to journalArticle

Roy, Chad J. ; Adams, A. Paige ; Wang, Eryu ; Plante, Kenneth ; Gorchakov, Rodion ; Seymour, Robert ; Vinet-Oliphant, Heather ; Weaver, Scott. / Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. In: Journal of Infectious Diseases. 2014 ; Vol. 209, No. 12. pp. 1891-1899.
@article{2b8e0552b331490b9df9c3565dd1d3c9,
title = "Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose",
abstract = "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes major epidemics of rash, fever, and debilitating arthritis. Currently, there are no vaccines or antivirals available for prevention or treatment. We therefore generated 2 live-attenuated vaccine candidates based on the insertion of a picornavirus internal ribosome entry site (IRES) sequence into the genome of CHIKV. Vaccination of cynomolgus macaques with a single dose of either vaccine produced no signs of disease but was highly immunogenic. After challenge with a subcutaneous inoculation of wild-type CHIKV, both vaccine candidates prevented the development of detectable viremia. Protected animals also exhibited no significant changes in core body temperature or cardiovascular rhythm, whereas sham-vaccinated animals showed hyperthermia, followed by sustained hypothermia, as well as significant changes in heart rate. These CHIKV/IRES vaccine candidates appear to be safe and efficacious, supporting their strong potential as human vaccines to protect against CHIKV infection and reduce transmission and further spread.",
keywords = "Chikungunya virus, nonhuman primates, viral vaccine",
author = "Roy, {Chad J.} and Adams, {A. Paige} and Eryu Wang and Kenneth Plante and Rodion Gorchakov and Robert Seymour and Heather Vinet-Oliphant and Scott Weaver",
year = "2014",
month = "6",
day = "15",
doi = "10.1093/infdis/jiu014",
language = "English (US)",
volume = "209",
pages = "1891--1899",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose

AU - Roy, Chad J.

AU - Adams, A. Paige

AU - Wang, Eryu

AU - Plante, Kenneth

AU - Gorchakov, Rodion

AU - Seymour, Robert

AU - Vinet-Oliphant, Heather

AU - Weaver, Scott

PY - 2014/6/15

Y1 - 2014/6/15

N2 - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes major epidemics of rash, fever, and debilitating arthritis. Currently, there are no vaccines or antivirals available for prevention or treatment. We therefore generated 2 live-attenuated vaccine candidates based on the insertion of a picornavirus internal ribosome entry site (IRES) sequence into the genome of CHIKV. Vaccination of cynomolgus macaques with a single dose of either vaccine produced no signs of disease but was highly immunogenic. After challenge with a subcutaneous inoculation of wild-type CHIKV, both vaccine candidates prevented the development of detectable viremia. Protected animals also exhibited no significant changes in core body temperature or cardiovascular rhythm, whereas sham-vaccinated animals showed hyperthermia, followed by sustained hypothermia, as well as significant changes in heart rate. These CHIKV/IRES vaccine candidates appear to be safe and efficacious, supporting their strong potential as human vaccines to protect against CHIKV infection and reduce transmission and further spread.

AB - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes major epidemics of rash, fever, and debilitating arthritis. Currently, there are no vaccines or antivirals available for prevention or treatment. We therefore generated 2 live-attenuated vaccine candidates based on the insertion of a picornavirus internal ribosome entry site (IRES) sequence into the genome of CHIKV. Vaccination of cynomolgus macaques with a single dose of either vaccine produced no signs of disease but was highly immunogenic. After challenge with a subcutaneous inoculation of wild-type CHIKV, both vaccine candidates prevented the development of detectable viremia. Protected animals also exhibited no significant changes in core body temperature or cardiovascular rhythm, whereas sham-vaccinated animals showed hyperthermia, followed by sustained hypothermia, as well as significant changes in heart rate. These CHIKV/IRES vaccine candidates appear to be safe and efficacious, supporting their strong potential as human vaccines to protect against CHIKV infection and reduce transmission and further spread.

KW - Chikungunya virus

KW - nonhuman primates

KW - viral vaccine

UR - http://www.scopus.com/inward/record.url?scp=84901801189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901801189&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu014

DO - 10.1093/infdis/jiu014

M3 - Article

VL - 209

SP - 1891

EP - 1899

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -